Converging Factors Driving the Growth of Transdermal Patches for Neurology Indications

(Amherst, NH) – Despite recent progress in a number of therapeutic sectors, progress toward curative medicine for neurological and related central nervous system disorders has remained elusive. The result is a therapeutic sector that relies heavily on control of symptoms and palliative care. This disappointing picture is being exacerbated by disease trends that are increasing the morbidity and mortality associated with CNS ailments in the general population. These trends include the growing incidence of neurological disorders associated with longevity and aging, and significant increases in the number of children diagnosed with autism.

Neurological disorders are highly prevalent worldwide. The World Health Organization’s Global Burden of Disease report drew the attention of the international health community to the fact that the burden of mental and neurological disorders has been seriously underestimated by traditional epidemiological methods that took into account only mortality, but not disability rates. This report specifically showed that while the mental and neurological disorders are responsible for about one per cent of deaths, they account for almost 11 per cent of disease burden the world over.

Advancing age is the most significant risk factor for neurological disease. As the U.S. population grows older, the burden of neurological disease becomes ever more apparent. Costs associated with neurological diseases are expected to increase dramatically within the next few years and decades. Currently, hospital costs paid by Medicare and Medicaid are almost three times higher for those with neurological disease than for other conditions. Unless new and better means are discovered and deployed to manage these impairments, their costs are expected to increase dramatically over the next five years.

Because diseases of the central nervous system often result in compromised cognitive and/or motor skills that can increase the level of involuntary non-compliance with therapeutic protocols, transdermal delivery of drugs targeting CNS disorders is generally viewed as an approach that can increase patient safety and improve outcomes. In addition to the handful of FDA-approved transdermal CNS products, more than a dozen companies are currently pursuing a range of APIs in transdermal delivery systems that target neurological and CNS conditions. While none of these development-stage candidates is curative, the benefits they can offer in terms of patient ease-of-use, product safety and overall quality-of-care are expected to result in reduced morbidity and more effective symptom management for afflicted patients.

Greystone’s analysis of the global transdermal CNS market includes detailed product analysis, an assessment of factors influencing demand for transdermal CNS drug products, the key players in this segment, the regulatory and industry environment, and the dynamics of patient care that will affect market development. Available data also includes forecasts for the growth of transdermal CNS products.

More information is available at www.greystoneassociates.org .

Contact:

Mark Smith
Voice: 603-595-4340
Fax: 603-218-7020
www.greystoneassociates.org

Source: Greystone Research Associates

About Greystone

Greystone Associates is a medical technology consulting firm focused on the areas of medical market strategy, product commercialization, venture development, and market research. We assist medical and healthcare market participants in achieving their business objectives through the creation of detailed development strategies, product commercialization programs, and comprehensive market and technology research and analysis. Our market research publications are designed, researched and written to provide timely and insightful information and data on focused market segments, with the aim of providing market participants with the essential knowledge to refine and execute their marketing plans and financial targets.

Contact:

Mark Smith
Greystone Research Associates
98 Route 101A
Amherst, NH 03031 USA
Voice: 603-595-4340
Fax: 603-218-7020
www.greystoneassociates.org

This release was published on openPR.